TBIO.jpg
Translate Bio to Participate in Upcoming Investor Conferences
November 01, 2018 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially...
CureVac Logo mit Claim RGB.jpg
CureVac verkündet den Start einer klinischen Phase-I-Studie mit mRNA-basiertem Tollwutimpfstoff
October 23, 2018 07:13 ET | CureVac AG
Studie soll erste Daten zur intramuskulären Anwendung des von CureVac neu entwickelten Impfstoffs am Menschen liefern TÜBINGEN, Deutschland / BOSTON, USA, Oct. 23, 2018 (GLOBE NEWSWIRE) -- Das...
CureVac Logo mit Claim RGB.jpg
CureVac Announces First Study Participant Enrolled in Phase I Clinical Trial Testing Prophylactic mRNA Rabies Vaccine
October 23, 2018 07:00 ET | CureVac AG
Trial to provide first-in-human data for CureVac’s novel mRNA-based intramuscular rabies vaccine TÜBINGEN, Germany and BOSTON, Oct. 23, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated...
TBIO.jpg
Translate Bio to Present Preclinical Data Supporting MRT5005 at the 32nd Annual North American Cystic Fibrosis Conference
October 18, 2018 07:30 ET | Translate Bio, Inc.
-- Findings support ongoing Phase 1/2 study of once-weekly nebulized MRT5005 in adults with cystic fibrosis -- LEXINGTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Translate Bio, Inc. (Nasdaq:...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Announces Name Change to Adhera Therapeutics to More Closely Reflect the Mission of Improving Patient Outcomes
October 09, 2018 08:00 ET | Marina Biotech, Inc.
Research Triangle Park, NC, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Appoints Nancy R. Phelan to the Board of Directors
October 03, 2018 08:00 ET | Marina Biotech, Inc.
Research Triangle Park, NC, Oct. 03, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Appoints Eric Teague as Chief Financial Officer
September 24, 2018 08:00 ET | Marina Biotech, Inc.
Research Triangle Park, NC, Sept. 24, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...
TBIO.jpg
Translate Bio to Participate in Citi’s 13th Annual Biotech Conference
August 30, 2018 07:30 ET | Translate Bio, Inc.
LEXINGTON, Mass., Aug. 30, 2018 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative...
TBIO.jpg
Translate Bio Announces Second Quarter 2018 Financial Results and Highlights Recent Development and Corporate Achievements 
August 09, 2018 16:17 ET | Translate Bio, Inc.
-- Initiated Phase 1/2 clinical trial of MRT5005 in patients with cystic fibrosis ---- Established strategic mRNA vaccines partnership with Sanofi Pasteur ---- Completed initial public offering...
Marina-Biotech-Inc_Logo.jpg
Marina Biotech Appoints Jay D. Schwartz to serve as Senior Vice President, Commercial Operations
August 06, 2018 09:15 ET | Marina Biotech, Inc.
City of Industry, CA, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of...